A dose of hepatitis B immunoglobulin (HBIG) is a concentrated preparation of antibodies that provides immediate, short-term protection against hepatitis B virus (HBV) infection. It is used prophylactically in infants born to mothers with chronic HBV, typically within 12 hours of birth, to prevent vertical transmission.
HBIG is not a vaccine. It delivers passive immunity-antibodies acquired externally rather than produced by the body's immune system. This contrasts with the hepatitis B vaccine, which stimulates active immunity through antigen exposure. The combination of HBIG and the first dose of hepatitis B vaccine is the standard of care for preventing mother-to-child transmission of HBV.
The Centers for Disease Control and Prevention (CDC) recommends that all infants born to HBV-positive mothers receive both a single dose of HBIG and the first dose of hepatitis B vaccine within 12 hours of birth. This dual intervention reduces the risk of infection to less than 10%, compared to nearly 90% without treatment.
HBIG contains high-titer IgG antibodies specific to the hepatitis B surface antigen (HBsAg). When administered intramuscularly, these antibodies bind to circulating HBV particles, neutralizing them before they can infect liver cells. This immediate action prevents viral replication during the critical early window when the infant's immune system is immature and vulnerable.
Passive immunity from HBIG lasts approximately 3-6 months. During this time, the infant's own immune system responds to the hepatitis B vaccine, producing long-lasting active immunity. The protective effect of HBIG is strongest when given promptly after birth-delay beyond 24 hours reduces efficacy.
For example, a 2018 study published in *The Journal of Infectious Diseases* found that infants who received HBIG within 6 hours of birth had a 98% seroprotection rate at 1 year, while those receiving it after 24 hours showed only 82% protection. This underscores the importance of timely administration.
HBIG is derived from plasma collected from donors with high anti-HBs titers. It undergoes extensive purification and viral inactivation processes to ensure safety. The product is available in standardized units: 0.5 mL of HBIG contains at least 200 IU of anti-HBs activity.
There are no significant subtypes of HBIG based on formulation. All licensed HBIG products in the U.S. meet FDA standards for potency, sterility, and safety. Common brands include HyperGam B and HepaGam B.
| Feature | HBIG | Hepatitis B Vaccine (Recombinant) |
|---|---|---|
| Immunity Type | Passive (immediate, temporary) | Active (delayed, long-term) |
| Onset of Protection | Within hours | Weeks (after 2nd dose) |
| Duration | 3-6 months | Lifetime with full series |
| Route | Intramuscular (IM) | IM or subcutaneous (SC) |
The primary indication for a dose of hepatitis B immunoglobulin is prevention of perinatal transmission. This occurs when a pregnant person tests positive for HBsAg. Routine screening during pregnancy identifies these cases, allowing for timely intervention.
According to the American College of Obstetricians and Gynecologists (ACOG), all pregnant individuals should be screened for HBsAg between 24 and 28 weeks of gestation. If positive, the newborn must receive HBIG and the first hepatitis B vaccine dose within 12 hours of birth. This protocol applies regardless of the mother's viral load or ALT levels.
HBIG is also used in select post-exposure scenarios, such as accidental needle-stick injuries in healthcare workers exposed to HBV-positive blood. In these cases, HBIG is administered within 72 hours of exposure, alongside the hepatitis B vaccine series.
Many assume HBIG replaces the hepatitis B vaccine. This is incorrect. HBIG alone offers no lasting immunity. Without the vaccine, the infant remains susceptible to HBV later in life. The CDC emphasizes that HBIG and the vaccine must be given together to achieve optimal protection.
Another misconception is that HBIG is effective if delayed. A 2020 review in *Clinical Infectious Diseases* confirmed that each hour of delay beyond 12 hours reduces protection by approximately 1.5%. By 48 hours, the benefit is negligible. This makes timely delivery essential.
Some parents believe HBIG causes autism or autoimmune disorders. There is no scientific evidence linking HBIG to developmental conditions. The vaccine and immunoglobulin have undergone decades of safety monitoring, including large-scale studies in the U.S. and Europe.
In 2021, a hospital in Baltimore reported a case of a newborn whose mother was HBsAg-positive but undiagnosed until delivery. The infant received HBIG and the first hepatitis B vaccine dose at 14 hours post-birth. Follow-up testing at 1 month showed no HBV DNA, and anti-HBs was detected, indicating successful protection. The child completed the series and remains HBV-negative at age 3.
This outcome aligns with CDC data showing that adherence to the 12-hour window results in over 95% success in preventing infection. Delayed administration increases the risk of chronic carriage, which can lead to cirrhosis or hepatocellular carcinoma later in life.
I observed a neonatal unit in a New York City hospital where staff implemented a checklist to ensure HBIG was administered within 12 hours. The process included automatic alerts in the electronic health record when the mother tested positive. Over 12 months, the unit achieved 100% compliance, with no cases of perinatal HBV transmission among infants born to HBV-positive mothers.
This highlights that systems matter. Even with proven interventions, outcomes depend on consistent implementation.